Niva Natan

418 total citations
12 papers, 320 citations indexed

About

Niva Natan is a scholar working on Infectious Diseases, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Niva Natan has authored 12 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 6 papers in Molecular Biology and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Niva Natan's work include SARS-CoV-2 and COVID-19 Research (6 papers), Receptor Mechanisms and Signaling (4 papers) and Neuroscience and Neuropharmacology Research (3 papers). Niva Natan is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (6 papers), Receptor Mechanisms and Signaling (4 papers) and Neuroscience and Neuropharmacology Research (3 papers). Niva Natan collaborates with scholars based in Israel, United States and Bulgaria. Niva Natan's co-authors include Rachel Brandeis, Abraham Fisher, Zipora Pittel, Hagar Sonego, Nira Bar-Ner, Rachel Haring, Frank M. LaFerla, Rodrigo Medeiros, Eytan Gershonov and Daniel A. Ryskamp and has published in prestigious journals such as Molecules, Biotechnology and Bioengineering and Alzheimer s & Dementia.

In The Last Decade

Niva Natan

12 papers receiving 309 citations

Peers

Niva Natan

MB

PHARM

CMN

PHYSI

CTM

Raquel Herrero-Labrador Spain

Lenka Hromádková Czechia

Tanaporn Wangsanut Thailand

Fatemeh Goshadrou Iran

Yixiang Jiang China

Federica Fusco Italy

Sergio B. Socías Argentina

Arturo R. Viscomi Italy

Daniela Fenili Canada

Yingjie Qi China

Raquel Herrero-Labrador Spain

Niva Natan

165 ×0.9

MB

145 ×1.3

PHARM

117 ×1.2

CMN

96 ×1.0

PHYSI

74 ×1.4

CTM

Citations per year, relative to Niva Natan Niva Natan (= 1×) peers Raquel Herrero-Labrador

Countries citing papers authored by Niva Natan

Since Specialization

Citations

This map shows the geographic impact of Niva Natan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niva Natan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niva Natan more than expected).

Fields of papers citing papers by Niva Natan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niva Natan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niva Natan. The network helps show where Niva Natan may publish in the future.

Co-authorship network of co-authors of Niva Natan

This figure shows the co-authorship network connecting the top 25 collaborators of Niva Natan. A scholar is included among the top collaborators of Niva Natan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niva Natan. Niva Natan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Cherry, Lilach, Edith Lupu, Niva Natan, et al.. (2024). Development and Validation of a Plaque Assay to Determine the Titer of a Recombinant Live-Attenuated Viral Vaccine for SARS-CoV-2. Vaccines. 12(4). 374–374. 1 indexed citations

2.

Cherry, Lilach, et al.. (2022). Application of Ambr15 system for simulation of entire SARS‐CoV ‐2 vaccine production process involving macrocarriers. Biotechnology Progress. 38(5). e3277–e3277. 5 indexed citations

3.

Rosen, Osnat, et al.. (2022). Optimization of VSV‐ΔG‐spike production process with the Ambr15 system for a SARS‐COV‐2 vaccine. Biotechnology and Bioengineering. 119(7). 1839–1848. 7 indexed citations

4.

Rosen, Osnat, et al.. (2021). Novel method for quantifying cells on carriers and its demonstration during SARS‐2 vaccine development. Biotechnology and Bioengineering. 118(10). 3811–3820. 2 indexed citations

5.

Natan, Niva, et al.. (2021). Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries. Molecules. 26(11). 3213–3213. 27 indexed citations

6.

Oren, Ziv, Yaakov Adar, Lilach Cherry, et al.. (2021). Highly Efficient Purification of Recombinant VSV-∆G-Spike Vaccine against SARS-CoV-2 by Flow-Through Chromatography. BioTech. 10(4). 22–22. 15 indexed citations

7.

Rosen, Osnat, et al.. (2021). Poly(vinyl alcohol)‐methacrylate with CRGD peptide: A photocurable biocompatible hydrogel. Journal of Tissue Engineering and Regenerative Medicine. 16(2). 140–150. 8 indexed citations

8.

Fisher, Abraham, Ilya Bezprozvanny, Lili Wu, et al.. (2015). AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease. Neurodegenerative Diseases. 16(1-2). 95–110. 65 indexed citations

9.

Fisher, Abraham, Rodrigo Medeiros, Nira Bar-Ner, et al.. (2014). M1 MUSCARINIC AGONISTS AND A MULTIPOTENT ACTIVATOR OF SIGMA1/M1 MUSCARINIC RECEPTORS: FUTURE THERAPEUTICS OF ALZHEIMER'S DISEASE. Alzheimer s & Dementia. 10(4S_Part_1). 3 indexed citations

10.

Fisher, Abraham, Zipora Pittel, Rachel Haring, et al.. (2003). M<sub>1</sub> Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future Therapy. Journal of Molecular Neuroscience. 20(3). 349–356. 116 indexed citations

11.

Fisher, Abraham, et al.. (2002). AF150(S) and AF267B. Journal of Molecular Neuroscience. 19(1-2). 145–153. 60 indexed citations

12.

Fisher, Abraham, Rachel Brandeis, Rachel Haring, et al.. (2002). Impact of muscarinic agonists for successful therapy of Alzheimer’s disease. Journal of neural transmission. Supplementum. 189–202. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact